Drugs / JLP-2004
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06431399 | Apr → Jun 2024 | — | Jeil Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06169059 | Oct → Nov 2023 | — | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JLP-2004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06431399 ↗ |
| Action | Inhibit | “COX-2 inhibitor” NCT06169059 ↗ |